CellCarta and Imagene AI expanded their partnership to help convert AI pathology capabilities into companion diagnostic (CDx) programs, with an emphasis on analytical validation, trial-enrollment coordination, and regulatory support. The collaboration targets multiple sponsored biomarker programs, including work tied to non-small cell lung cancer CDx development. Imagene AI’s Lung Prediction Panel is being used for NSCLC, while CellCarta contributes assay-focused development—ranging from IHC quantification and H&E-based prediction through fit-for-purpose analytical testing for regulatory submission. The companies said the goal is a single-partner pathway that carries programs from algorithm performance to scaled, clinically deployable assays. The update reflects a broader shift in AI pathology from prototype models toward operational regulatory readiness, where CDx requirements like global enrollment and validation plans often determine whether algorithms translate into usable tests. Executives cited the need for practical development infrastructure rather than stand-alone performance metrics.